Table 2 Clinical findings
From: FabAV antivenin use after copperhead snakebite: clinically indicated or knee-jerk reaction?
Bite location | Total (318) | FabAV (44) | No FabAV (274) | p | |
|---|---|---|---|---|---|
Upper (%) | 130 (40.9 %) | 35 (80 %) | 95 (35 %) | <0.0001 | |
Lower (%) | 185 (58.2 %) | 9 (20 %) | 176 (64 %) | ||
Torso | 3 (<1 %) | 0 | 3 (<1 %) | ||
Systemic symptoms | |||||
Cardiovascular symptoms | 31 (9.7 %) | 8 (18.2 %) | 23 (8.4 %) | <0.05 | |
Constitutional symptoms | 24 (17.3 %) | 5 (11.4 %) | 19 (6.9 %) | NS | |
Abnormal coagulation tests | 75 (23.6 %) | 13 (29.5 %) | 62(22.6 %) | NS | |
Local symptoms | |||||
Numbness | 19 (6.0 %) | 4 (9.1 %) | 15 (5.5 %) | NS | |
Bruising | 26 (8.2 %) | 5 (11.4 %) | 21 (7.7 %) | NS | |
Erythema | 112 (35.2 %) | 16 (36.4 %) | 96 (35.0 %) | NS | |
Swelling – Degree | |||||
None (0) | 50 (15.7 %) | 1 (2.3 %) | 49 (17.9 %) | <0.005 | |
Mild (1) | 235 (73.9 %) | 34 (77.3 %) | 201 (73.4 %) | ||
Moderate (2) | 33 (10.4 %) | 9 (20.5 %) | 24 (8.8 %) | ||
Severe (3) | 0 | 0 | 0 | ||
Median (IQR) | 1 (1,1) | 1 (1,1) | 1 (1,1) | ||
Pain – Degree | |||||
Mild (1) | 254 (79.9 %) | 38 (86.4 %) | 216 (78.9 %) | NS | |
Moderate (2) | 49 (15.4 %) | 3 (6.8 %) | 46 (16.8 %) | ||
Severe (3) | 15 (4.7 %) | 3 (6.8 %) | 12 (4.4 %) | ||
Median (IQR) | 1 (1,1) | 1 (1,1) | 1 (1,1) | ||